Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 30 November 2022, 08:31 HKT/SGT
Share:
        

Source: Eisai / Biogen
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine

TOKYO, Nov 30, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were published in the New England Journal of Medicine, one of the world's most prestigious peer-reviewed medical journals. For the details of the paper, please refer to: www.nejm.org/doi/full/10.1056/NEJMoa2212948.

The rapid publication of the Clarity AD study results demonstrates Eisai's strong commitment to trust and transparency based on Eisai's human health care mission. Eisai and Biogen remain committed to disclosing data and information on lecanemab. If approved, we will work to bring the drug expeditiously to people living with early AD and their families.

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such an investigational agent will successfully gain health authority approval.

For more information, visit www.eisai.com/news/2022/pdf/enews202284pdf.pdf.


Topic: Press release summary
Source: Eisai / Biogen

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 29, 2025 08:01 HKT/SGT
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
July 25, 2025 12:31 HKT/SGT
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
July 23, 2025 09:07 HKT/SGT
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
July 22, 2025 10:56 HKT/SGT
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
July 16, 2025 13:50 HKT/SGT
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
July 14, 2025 09:20 HKT/SGT
"URECE" (Dotinurad) Launched in China as a treatment for Gout
July 8, 2025 08:31 HKT/SGT
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
June 2, 2025 16:46 HKT/SGT
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
May 28, 2025 16:45 HKT/SGT
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 21, 2025 14:00 HKT/SGT
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: